ArticleBJPsych open2020
Inflammation as a treatment target in mood disorders: review.
Article in BJPsych open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05487885 (Anhedonia, Development, and Emotions), which is not on this map. Cited by 55 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study
Who cites it
55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Blunted Niacin Skin Flushing Response in Mood Disorders: A Meta-Analysis of Case-Control Studies.Depression and anxiety · 2026Pooled it
- Carnosine/histidine-containing dipeptide supplementation improves depression and quality of life: systematic review and meta-analysis of randomized controlled trials.Nutrition reviews · 2025Pooled it
- Comparison with healthy controls: meta-analysis of changes in intestinal flora in Chinese patients with irritable bowel syndrome.Frontiers in cellular and infection microbiology · 2025Pooled it
- Whole blood mitochondrial copy number in clinical populations with mood disorders: A meta-analysis: Blood mitochondrial copy number and mood disorders.Psychiatry research · 2024Pooled it
- Does psychological treatment of major depression reduce cardiac risk biomarkers? An exploratory randomized controlled trial.Psychological medicine · 2023Trial
- Neural response to reward as a potential pathway from inflammation to anhedonia in adolescents at risk for depression.Brain, behavior, & immunity - health · 2026Article
- Topical editorials, papers and commentaries: next 10 years.BJPsych open · 2026Article
- Genotype epigenome phenotype integration reveals peripheral immune contributions to type I bipolar disorder.Nature communications · 2026Article
- Integrated Chemometric and Machine Learning Analysis Identifies Peripheral Biosignatures Distinguishing Major Depressive Disorder from Bipolar Disorder: A Translational Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Insomnia: the gut microbiome connection, prospects for probiotic and postbiotic therapies, and future directions.Journal of advanced research · 2026Review
- Differential Effects of Oleoyl Serine and HU-910 on Anxiety-like and Depression-like Behaviors in Male and Female WKY Rats.International journal of molecular sciences · 2026Article
- Time-restricted feeding rescues sociability deficits and reduces neuroinflammation in aged mice.Neurobiology of aging · 2026Article
- Article
- Causal influences of migraine on neuropsychiatric disorders: A 2-sample Mendelian randomization study.Medicine · 2025Article
- Associations between prenatal inflammation and dimensions of depressive symptoms across the perinatal period.Psychoneuroendocrinology · 2025Article
- Coffee intake is associated with telomere length in severe mental disorders.BMJ mental health · 2025Article
- Bipolar and major depressive disorders: associations with serum zonulin levels and rs2070937 polymorphism.BMC psychiatry · 2025Article
- The Gut Microbiome and Its Impact on Mood and Decision-Making: A Mechanistic and Therapeutic Review.Nutrients · 2025Review
- Review
- Mental Ill-Health in young people with systemic autoinflammatory disease - a scoping review.Rheumatology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMood disorders, i.e. major depressive disorder (MDD) and bipolar disorders, are leading sources of disability worldwide. Currently available treatments do not yield remission in approximately a third of patients with a mood disorder. This is in part because these treatments do not target a specific core pathology underlying these heterogeneous disorders. In recent years, abnormal inflammatory processes have been identified as putative pathophysiological mechanisms and treatment targets in mood disorders, particularly among individuals with treatment-resistant conditions.
aimsIn this selective review, we aimed to summarise recent advances in the field of immunopsychiatry, including emerging pathophysiological models and findings from treatment ttrials of immunomodulatory agents for both MDD and bipolar disorders.
methodWe performed a literature review by searching Medline for clinical trials of immunomodulating agents as monotherapy or adjunctive treatments in MDD and bipolar disorders. Included studies are randomised controlled trials (RCTs), cluster RCTs or cross-over trials of immunomodulating agents that had an active comparator or a placebo-arm.
resultsCurrent evidence shows an association between inflammation and mood symptoms. However, there is conflicting evidence on whether this link is causal.
conclusionsFuture studies should focus on identifying specific neurobiological underpinnings for the putative causal association between an activated inflammatory response and mood disorders. Results of these studies are needed before further treatment trials of immunomodulatory agents can be justified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.